Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Common Equity (2018 - 2025)

Historic Common Equity for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $6.8 million.

  • BioNexus Gene Lab's Common Equity fell 2739.52% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 2739.52%. This contributed to the annual value of $8.3 million for FY2024, which is 1382.34% down from last year.
  • As of Q3 2025, BioNexus Gene Lab's Common Equity stood at $6.8 million, which was down 2739.52% from $7.5 million recorded in Q2 2025.
  • Over the past 5 years, BioNexus Gene Lab's Common Equity peaked at $9.7 million during Q3 2023, and registered a low of $6.0 million during Q2 2023.
  • In the last 5 years, BioNexus Gene Lab's Common Equity had a median value of $7.1 million in 2022 and averaged $7.6 million.
  • In the last 5 years, BioNexus Gene Lab's Common Equity surged by 6006.25% in 2024 and then plummeted by 2739.52% in 2025.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Common Equity stood at $7.2 million in 2021, then decreased by 7.17% to $6.7 million in 2022, then skyrocketed by 44.9% to $9.7 million in 2023, then fell by 13.82% to $8.3 million in 2024, then dropped by 18.1% to $6.8 million in 2025.
  • Its Common Equity stands at $6.8 million for Q3 2025, versus $7.5 million for Q2 2025 and $7.8 million for Q1 2025.